Skip to content

Author

Zhi-Xiong Yang

We have 2 of 16 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Aug 2026

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Mefatinib demonstrated superior efficacy to gefitinib with a similar tolerability profile in the first-line treatment of EGFR-mutated advanced NSCLC with common and uncommon EGFR-activating mutations.

Jia Yu, Anwen Xiong, Qi-Ming Wang et al. · 0 citations
Sep 2026

Identification of Causal Plasma Proteins and Immune Mediators for Lung Cancer in Never-Smokers: A Large-Scale Integrative Analysis Combining Mendelian Randomization, Colocalization, and Mediation.

Genetically proxied plasma RARRES1 is associated with increased LCINS risk and may contribute to disease susceptibility through immune-related alterations involving NKT-cell phenotypes, providing biologically plausible evidence supporting a role for RARRES1 in LCINS pathogenesis and its potential utility in biomarker d...

Jian-Cong Wu, Qi Zhang, Yan-Ming Lin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.